

Chordate presents at the Feminvest investor conference in Oslo

Chordate Medical's Caroline Lundgren Brandberg, non-executive Director and main owner, will participate in the Fearless investor conference hosted by Feminvest in Oslo on April 25th, where she will present Chordate Medical and Ozilia Migraine. Chordate's chairman, Henrik Rammer, will also be present in Oslo. Feminvest is the largest network for female investors and entrepreneurs in the Nordic region.

"Our participation at Feminvest aligns with our increasing focus on raising awareness about the company and Ozilia across various industry and investor segments. Feminvest has a strong network of investors focused specifically on femtech and life science, where Ozilia fits into both areas," says Caroline Lundgren Brandberg, non-executive Director of Chordate Medical.

Feminvest is an acceleration network for female ownership through education, as well as an investment venture. It is currently the largest hub for female investors and entrepreneurs in the Nordic region with almost 47,000 subscribers. Feminvest also operates a network of 300 female angel investors. For Chordate Medical, the investor event in Oslo on April 25 is one of several meeting points during the spring. On the same date, the company's CEO, Anders Weilandt, will be in Switzerland showcasing Ozilia at a joint congress for specialist associations from Switzerland, Germany, and Austria.

"As Ozilia gains increasing acceptance and success in our target markets, it is natural for us to expand efforts to raise awareness for Ozilia among potential investors and buyers of the company," says Anders Weilandt, CEO of Chordate.

Caroline Lundgren Brandberg, MSc. Eng. Physics, eMBA, has been a board member of Chordate Medical since 2021. Caroline is the Global Sales Director at climate tech company Deedster and has previously worked internationally for Ericsson in various leadership roles with a focus on sales and marketing. She also holds several board and advisory board positions, including at Stockholm University.

[Read more about Feminvest Fearless](#)

For more information, please contact:

Anders Weilandt, CEO

anders.weilandt@chordate.com

Cell: +46 733-874277

About Chordate

Chordate Medical Holding AB (publ) is a medical technology company that has developed, patented and CE-marked Ozilia® Migraine (formerly K.O.S), a neuromodulation and drug-free treatment technology for chronic migraine and chronic rhinitis. The treatment has clinically proven efficacy according to a recent study, and is marketed in selected markets in the EU and the Middle East. Chordate Medical is listed on Nasdaq First North Growth Market Stockholm (ticker: CMH). Read more at www.chordate.com

The company's Certified Adviser on Nasdaq First North Growth Market Stockholm is Vator Securities AB.

N.B. The English text is an in-house translation of the original Swedish text. Should there be any disparities between the Swedish and the English text, the Swedish text shall prevail.

Image Attachments

[Caroline Lundgren Brandberg](#)

Attachments

[Chordate presents at the Feminvest investor conference in Oslo](#)